By Leila Martyn, Founder of MyOva

Nobody warned you.

That's the thing most women say, eventually. Looking back, they can trace the beginning: the sleep that stopped working, the anxiety that appeared from nowhere, the periods that suddenly became unpredictable after decades of regularity, the brain that felt like it was operating through fog. But they didn't have a name for it. They didn't know it could start in their early forties. They didn't know it could last the better part of a decade.

They went to their GP and were told their bloods were normal. Or were offered antidepressants. Or were told "it's probably your age."

Perimenopause is one of the most significant physiological transitions a woman moves through in her lifetime. It affects every system in the body, not just the reproductive system. It reshapes metabolism, brain chemistry, cardiovascular function, bone density, mood, sleep architecture, and stress resilience. And yet most women enter it completely unprepared, and most healthcare encounters fail to explain what is actually happening.

This guide is the thing most women wish they'd had earlier. It covers what perimenopause actually is, what drives every symptom, how to tell the difference between perimenopause and other conditions, what the long-term health picture looks like, and what an evidence-based approach to navigating it looks like in practice. No fluff, no "embrace the change" platitudes. Just clear, clinically grounded information that treats you as the intelligent adult you are.

---

What Is Perimenopause? The Definition That Actually Makes Sense

Short answer: Perimenopause is the hormonal transition leading up to menopause, defined by increasingly irregular ovulation and erratically fluctuating oestrogen, and it typically spans several years.

Perimenopause is the hormonal transition period leading up to menopause, defined clinically as the point at which a woman has not had a period for 12 consecutive months [1]. Everything before that 12-month mark, from the first signs of hormonal change, is perimenopause.

In the UK, the average age for menopause is 51 [1, 2]. But averages hide a wide range. Some women begin experiencing perimenopausal symptoms in their late thirties. Some don't notice significant changes until their late forties. There is no single timeline, and the internationally recognised staging framework for the menopause transition, known as STRAW+10, defines perimenopause by the pattern of hormonal and cycle change rather than by age alone [3].

What defines perimenopause is not a specific age. It is a specific hormonal pattern: the beginning of ovarian decline, characterised by increasingly irregular ovulation, rising FSH (follicle-stimulating hormone), and the erratic fluctuation, not the steady decline, of oestrogen [3].

This distinction matters enormously. Perimenopause is not simply "low oestrogen." In early perimenopause especially, oestrogen can spike higher than it did during the reproductive years before dropping. It's the unpredictability and eventual loss of rhythm that drives symptoms, not a linear decline from high to low [3].

Perimenopause does not follow a fixed timeline. For many women it spans several years; for some, it extends closer to a decade [4]. The experience of it varies significantly between women: some have relatively few symptoms, while others experience a degree of disruption that meaningfully affects their work, relationships, cognitive function, and quality of life.

You are not imagining it. And you were not supposed to just get on with it.

The Two Stages of Perimenopause

Understanding where you are in the transition helps enormously with both diagnosis and expectations.

Early perimenopause is characterised by changes in menstrual cycle pattern, cycles becoming slightly shorter, longer, heavier, lighter, or more irregular, while periods are still occurring with some regularity. FSH begins to rise as the brain attempts to stimulate increasingly unresponsive ovaries. Oestrogen may spike unpredictably. Progesterone production, which depends on ovulation occurring, begins to decline as ovulatory cycles become less consistent [3].

The symptom experience in early perimenopause is often dominated by psychological symptoms, anxiety, mood changes, brain fog, sleep disruption, rather than the hot flushes most women associate with menopause. This is one of the main reasons perimenopause is missed or misdiagnosed: the psychological symptoms arrive first, without the classic vasomotor symptoms that prompt recognition.

Late perimenopause is characterised by the STRAW+10 framework as cycles of 60 days or longer between periods, more pronounced vasomotor symptoms as oestrogen levels fall more consistently, and accelerating bone loss [3]. FSH levels are significantly elevated. Hot flushes and night sweats are more likely to be prominent in this stage.

Both stages require understanding. Both stages are manageable. Neither stage requires simply enduring symptoms without investigation or support.

What Is Actually Happening in Your Hormones

Short answer: Three hormones drive the perimenopausal experience: erratically fluctuating oestrogen, early-declining progesterone, and steadily rising FSH as the ovaries respond less predictably.

This is the section that changes how women understand their experience. Because once the mechanism is clear, the symptoms stop feeling random.

The Role of Oestrogen

Oestrogen is not a single hormone. It is a class of hormones, predominantly oestradiol during the reproductive years, that regulates far more than the reproductive system. A major review describing perimenopause as a "neurological transition state" sets out oestrogen's wide-reaching influence across the brain and body, including [5]:

• Brain function: serotonin synthesis and receptor sensitivity, dopamine signalling, synaptic plasticity, and cerebral blood flow
• Thermoregulation: the hypothalamic thermostat that controls body temperature
• Bone metabolism: inhibiting bone resorption and protecting bone density
• Cardiovascular function: arterial compliance, lipid metabolism, and vascular inflammation
• Metabolic regulation: insulin sensitivity, fat distribution, and glucose metabolism
• Vaginal and urogenital tissue: mucosal integrity, pH, and pelvic floor support

When oestrogen fluctuates erratically, spiking and plunging unpredictably rather than following the reliable rhythm of the reproductive years, every one of these systems is affected [5]. This is why perimenopause is not a reproductive condition. It is a whole-body transition.

The Role of Progesterone

Progesterone often receives less attention than oestrogen in perimenopause discussions, but its decline is frequently the first hormonal shift and often the driver of the earliest symptoms.

Progesterone is produced by the corpus luteum after ovulation. As perimenopause approaches and ovulation becomes less frequent or less complete, progesterone output falls, often significantly, while oestrogen may still be fluctuating at relatively high levels [3].

Low progesterone has specific neurological effects. Progesterone metabolises to allopregnanolone, a neurosteroid that enhances GABA receptor activity in the brain, and research into allopregnanolone's role in mood and anxiety disorders describes this calming, sleep-supportive effect in detail [6]. When progesterone declines, the brain loses a natural calming buffer. The result is often anxiety, sleep fragmentation, night-time wakefulness, and emotional lability, appearing before hot flushes, often before cycle changes are dramatic, and almost invariably before a GP considers perimenopause as a diagnosis.

The Role of FSH

As ovarian responsiveness declines, the pituitary gland works harder, producing increasing amounts of FSH to try to stimulate follicle development. Rising FSH is a clinical marker of perimenopause, though it is not a reliable single-test diagnostic because levels fluctuate dramatically day to day in early perimenopause [3].

This is one of the most important things to understand about hormone testing in perimenopause: a single blood test showing "normal" FSH does not exclude perimenopause. A longitudinal picture, tracking symptoms alongside hormonal markers over time, is far more diagnostically informative than any single reading [1].

---

The Symptoms of Perimenopause: Every One Explained

The British Menopause Society identifies more than 30 potential symptoms of perimenopause [13]. Most women experience a subset, but that subset is often more extensive, and more disruptive, than they were prepared for.

Vasomotor Symptoms

Hot flushes and night sweats are the most recognised perimenopause symptoms, affecting around 75 to 80% of women during the menopausal transition [7]. They are driven by destabilisation of hypothalamic thermoregulation as oestrogen fluctuates. The thermostat's tolerance zone narrows, and what would previously have been an unremarkable change in core body temperature now triggers an emergency cooling response: rapid vasodilation, increased skin blood flow, and sweating.

Hot flushes are not cosmetic inconveniences. Severe hot flushes disrupt sleep, affect concentration, impair work performance, and for many women represent one of the most functionally significant aspects of perimenopause.

→ Read: Does Sage Actually Help With Hot Flushes? Here's What the Research Says

→ Read: Red Clover for Menopause: Plant Oestrogen or Overhyped Herb?

Sleep Disruption

Sleep problems are common during the menopausal transition, and research following women across this transition has consistently found disrupted sleep becoming more prevalent as women move from premenopause into perimenopause [8]. The mechanisms are multiple and interrelated:

• Night sweats interrupt sleep continuity directly
• Declining progesterone reduces GABA-mediated sleep onset and depth [6]
• Rising cortisol can disrupt circadian rhythm and contribute to early morning waking
• Anxiety, itself hormonally driven, prevents sleep onset

Sleep disruption in perimenopause is not simply a matter of managing hot flushes. It is a neurological and hormonal phenomenon requiring a multifaceted approach. And disrupted sleep compounds virtually every other perimenopausal symptom, worsening brain fog, amplifying mood instability, accelerating metabolic changes, and reducing stress resilience.

Mood Changes, Anxiety and Depression

A meaningful proportion of perimenopausal women experience clinically significant anxiety or depression, with research from the long-running Study of Women's Health Across the Nation finding mood symptoms rising specifically during the menopause transition itself, not simply with age [9]. This is not a coincidence, and it is not a psychological response to "getting older."

Oestrogen directly influences serotonin synthesis and receptor sensitivity. As oestrogen fluctuates, so does the stability of the serotonergic system [5]. Progesterone decline removes the GABA-calming buffer [6]. And a heuristic model developed specifically to explain perimenopausal depression proposes that the HPA axis, the body's stress response system, becomes dysregulated as ovarian hormones fluctuate, amplifying cortisol responses to ordinary life stressors [10].

The result is anxiety that feels disproportionate, low mood that doesn't track with life circumstances, emotional volatility, and sometimes depression, in women who have never previously experienced mental health difficulties.

The most important clinical distinction here: mood symptoms in perimenopause often have a hormonal driver. Treating them with antidepressants alone, without addressing the underlying endocrine shift, can produce limited improvement for some women, because the root cause remains unaddressed. This is a decision to make with your GP, not instead of one.

→ Read: Mastering Hormone Balance: A Comprehensive Guide to Understanding Your Hormones

Brain Fog and Cognitive Changes

Brain fog, the experience of reduced mental sharpness, memory lapses, difficulty concentrating, reduced verbal fluency, is one of the most distressing and least discussed symptoms of perimenopause.

A systematic review and meta-analysis of cognition and mood in perimenopause found measurable, if modest, dips in some cognitive domains during the transition, rooted in oestrogen's influence on dopamine signalling, synaptic plasticity, and cerebral blood flow [5, 11]. When oestrogen fluctuates, cognitive performance fluctuates with it. Women frequently report feeling cognitively unreliable, unable to trust their memory or concentration in the way they always had.

The research is reassuring on one critical point: the cognitive changes of perimenopause are not evidence of permanent neurodegeneration. For most women, cognitive performance stabilises as the transition completes [11]. This is not the beginning of dementia. It is a transitional neurological adjustment, significant and disruptive, but not irreversible.

Irregular Periods

Cycle changes are among the first signs of early perimenopause, and they are highly variable. Cycles may become shorter, then longer. Periods may become heavier before eventually lightening. Spotting between periods may appear. Cycles may be skipped entirely [3].

The mechanism is straightforward: as ovulation becomes less reliable, the progesterone signal that triggers menstruation becomes inconsistent. Without adequate progesterone, the endometrium may build up for longer before shedding, resulting in heavier, more prolonged periods. Anovulatory cycles, cycles in which no egg is released, produce oestrogen without the progesterone counterbalance, compounding this effect.

Heavy perimenopausal periods are common and deserve investigation, both to confirm the hormonal cause and to rule out other causes including fibroids, endometriosis, and in rare cases, endometrial pathology.

Weight Changes and Metabolic Shifts

Many women notice weight redistribution during perimenopause, specifically, fat accumulation around the abdomen, even without significant changes to diet or exercise. This is not a failure of discipline. It is a metabolic recalibration that tracks alongside hormonal change, with research on cardiovascular and bone health in the menopause transition documenting shifts in cholesterol and other metabolic markers as oestrogen declines [12].

Oestrogen plays a protective role in insulin sensitivity and metabolic function. As it declines, insulin resistance tends to increase for many women. The liver's handling of lipids also changes, with total cholesterol and LDL typically rising as oestrogen declines [12].

Muscle mass preservation becomes particularly important during this period. Lean muscle is a primary driver of insulin sensitivity and metabolic rate. Prioritising resistance training, adequate protein intake, and sleep quality are among the most evidence-backed strategies for managing perimenopausal metabolic shifts.

Joint Pain and Physical Changes

Joint aches, stiffness, and musculoskeletal discomfort are frequently reported in perimenopause, and are often attributed to ageing rather than hormones. Oestrogen has anti-inflammatory properties and plays a role in joint lubrication and cartilage health. As levels fluctuate, inflammatory sensitivity increases and connective tissue becomes less well supported [13].

Vaginal and Urogenital Changes

Declining oestrogen affects the vaginal and urogenital tissues, thinning the vaginal mucosa, reducing natural lubrication, altering pH, and reducing the resilience of pelvic floor structures. Symptoms include vaginal dryness, discomfort during sex, urinary urgency, and increased susceptibility to urinary tract infections [13].

These symptoms, collectively termed the Genitourinary Syndrome of Menopause (GSM), are extremely common and extremely underreported due to the embarrassment many women feel about them. They are treatable, and they deserve a direct conversation with a healthcare provider.

---

Why Your Blood Tests Might Look "Normal" (But You're Not Fine)

Short answer: A single hormone test often looks normal in early perimenopause because levels fluctuate day to day, so NICE guidance recommends diagnosing women over 45 by symptoms, not blood tests.

This is one of the most frustrating aspects of perimenopause for women seeking diagnosis and validation.

Because perimenopause in its early stages is characterised by fluctuating rather than consistently low hormones, a single blood test, taken on any given day, may show oestrogen levels that appear within the normal reproductive range, FSH levels that don't yet indicate ovarian decline, and progesterone that looks adequate [3].

The result: a woman experiencing debilitating symptoms is told her bloods are normal. She is offered antidepressants. She leaves without a diagnosis.

The clinical picture is confirmed not by a single blood test but by the pattern of symptoms in context of age and cycle changes. NICE guidelines state that perimenopause should be diagnosed clinically, based on symptom history, in women aged 45 and over, without the need for confirmatory hormone testing [1].

If you are between 45 and 55 and experiencing symptoms consistent with perimenopause, you do not need a blood test to confirm the diagnosis. You need a clinician who understands how to take a proper symptom history and is willing to discuss your options.

If your GP dismisses your symptoms without this conversation, you are entitled to ask for a referral, to a gynaecologist with a specialist interest in menopause, a British Menopause Society-accredited specialist, or a menopause clinic.

---

The Long-Term Health Picture: Why Perimenopause Is More Than Symptoms

Oestrogen does not only regulate reproduction. Its decline creates specific long-term health considerations that most women are never told about, and the perimenopausal window is the optimal time to address them.

Bone Density

Oestrogen is a primary regulator of bone metabolism, inhibiting osteoclasts (bone-resorbing cells) and supporting bone formation. As it declines, bone resorption accelerates.

The Study of Women's Health Across the Nation (SWAN) followed a large, multi-ethnic cohort of women through the menopause transition and found that lumbar spine bone loss accelerates sharply in the year or so immediately around the final menstrual period, continuing at an elevated rate for a further year or two before gradually slowing [14]. A related analysis from the same research programme found that a meaningful minority of perimenopausal women lose bone density considerably faster than average during this window [15].

Bone loss is clinically silent. It goes unaddressed unless actively managed. Bone-protective strategies, resistance training, adequate calcium and vitamin D, and HRT consideration where appropriate, are most effective when begun during perimenopause, before significant structural compromise has occurred.

Cardiovascular Risk

As oestrogen declines, total cholesterol and LDL tend to rise, while HDL can fall [12]. Arterial stiffness increases for many women. The cardiovascular protective effect of oestrogen, which has maintained a more favourable risk profile than age-matched men throughout the reproductive years, is progressively reduced.

The perimenopausal decade is a meaningful window for cardiovascular prevention. The foundations built now can affect long-term outcomes.

Metabolic Health

Insulin resistance tends to increase as oestrogen declines, driving not just weight redistribution but broader shifts in metabolic markers including fasting glucose, blood pressure, and lipid profiles [12]. For women who already have PMOS (PCOS)-related insulin resistance, perimenopause can compound an existing vulnerability significantly, making metabolic strategy during this transition particularly important.

HRT: What the Evidence Actually Says

Short answer: HRT remains the most clinically effective treatment for perimenopausal symptoms, and current NICE and British Menopause Society guidance considers it safe for most healthy women under 60, within 10 years of menopause.

Hormone replacement therapy remains the most clinically effective intervention for perimenopausal and menopausal symptoms. The evidence for its effectiveness on vasomotor symptoms, sleep, mood, cognitive function, bone protection, and cardiovascular risk management, when initiated in the perimenopausal window, is substantial [1].

The fear surrounding HRT, largely stemming from the 2002 Women's Health Initiative study, which was widely misinterpreted and misreported in the years that followed, has been substantially revised by subsequent research. Current clinical consensus, as reflected in updated NICE guidance and British Menopause Society guidelines, supports HRT as a safe and effective option for most healthy women under 60 and within 10 years of menopause [1].

What the evidence supports:

• Body-identical (bioidentical) oestrogen delivered transdermally (patch, gel, spray) does not carry the same clotting and stroke risks associated with older oral synthetic oestrogen formulations
• Micronised progesterone is better tolerated than older synthetic progestins for many women
• The risk-benefit profile of HRT is favourable for most women experiencing moderate to severe symptoms
• Beginning HRT during the perimenopausal window, rather than waiting until postmenopause, appears to offer greater cardiovascular and cognitive benefit for many women

What the evidence doesn't support: treating HRT as suitable for every woman without individual assessment. Women with certain risk factors, personal history of oestrogen-sensitive cancers, certain clotting disorders, specific cardiovascular conditions, require individual evaluation and discussion with a specialist.

The decision about HRT is a clinical one that belongs between you and a clinician with appropriate expertise in menopause medicine. What this article can do is ensure you arrive at that conversation informed, neither frightened by outdated statistics nor uninformed about the benefits.

A Natural and Nutritional Support Strategy: What Has Evidence

Short answer: For women not taking HRT, red clover and sage have the most researched evidence base for vasomotor symptoms, alongside adaptogenic botanicals and anti-inflammatory nutrition.

For women who choose not to take HRT, are waiting to discuss it, or who want to support the hormonal transition through every available evidence-based strategy, the following areas have genuine research behind them.

Phytoestrogen Support

Phytoestrogens are plant compounds that interact mildly with oestrogen receptors, providing a degree of oestrogenic activity when circulating oestrogen is declining. Red clover isoflavones have one of the more researched evidence bases among botanicals for vasomotor symptoms: a 2021 systematic review and meta-analysis of multiple randomised controlled trials found a modest but statistically significant reduction in daily hot flush frequency, though improvements across broader menopausal symptom scales were inconsistent between studies [16]. Red clover has no authorised health claim under EU/GB law and is traditionally used rather than clinically proven for this purpose.

→ Read: Red Clover for Menopause: Plant Oestrogen or Overhyped Herb?

Shatavari (Asparagus racemosus) is an Ayurvedic botanical traditionally used for female hormonal transitions across the lifecycle. It has no authorised health claim and is included on the strength of traditional use rather than clinical trial evidence.

Vasomotor Symptom Support

Sage (Salvia officinalis) is one of the more clinically studied botanicals for hot flush relief. A 2011 multicentre trial found a 64% reduction in intensity-rated hot flushes over eight weeks among women taking a standardised sage extract [17]. Sage has no authorised EU/GB health claim; this is traditional use supported by an emerging, but still limited, clinical evidence base, not a guaranteed result.

→ Read: Does Sage Actually Help With Hot Flushes? Here's What the Research Says

Adaptogenic Stress Support

The HPA axis can become more reactive as oestrogen declines, meaning cortisol spikes more easily and is less efficiently cleared for some women, compounding both sleep disruption and mood instability [10]. Adaptogenic botanicals traditionally used to support the body's stress response are therefore of particular interest during perimenopause, although none carry an authorised health claim.

KSM-66® Ashwagandha is traditionally used and has been studied for stress resilience and sleep quality → Read our full Ashwagandha guide.

Holy Basil (Ocimum tenuiflorum) is traditionally used for stress support and is the subject of ongoing research into its effects on cortisol and blood sugar stability → Read: Holy Basil for Hormones: What the Research Actually Shows.

Anti-Inflammatory Nutrition

Systemic inflammation can rise as oestrogen declines, since oestrogen has anti-inflammatory properties and its loss removes a degree of inflammatory regulation the body has relied on for decades. Anti-inflammatory dietary patterns are one of the more directly actionable ways to support the hormonal transition.

Turmeric (curcumin) is traditionally used and is the subject of ongoing research into anti-inflammatory activity relevant to perimenopausal symptom management, though it carries no authorised health claim.

→ Read: Anti-Inflammatory Eating for Hormonal Health

The MyOva Hormone Balance Supplement

The MyOva Hormone Balance supplement brings together ten botanicals relevant to the perimenopausal transition, each included on the strength of traditional use or an emerging research base, alongside active B6:

• Red Clover (10:1 extract): a phytoestrogen-rich botanical traditionally used in midlife wellness routines
• Sage leaf (10:1 extract, 4% rosmarinic acid): traditionally used, with an emerging clinical evidence base specifically studied for hot flush and night sweat support
• Shatavari (5:1 extract): an Ayurvedic botanical traditionally used for hormonal transition across the lifecycle
• KSM-66® Ashwagandha: a well-researched adaptogenic extract, traditionally used to support the body's resilience to everyday stress
• Holy Basil (4:1 extract): traditionally used for stress support and blood sugar stability
• Chamomile (10:1 extract): traditionally valued for gentle calming properties
• Turmeric (95% curcuminoids): traditionally used and studied for anti-inflammatory activity
• Rosemary (10:1 extract): traditionally used for general wellbeing
• Fennel (6:1 extract): traditionally used for cycle and digestive comfort
• Vitamin B6 as Pyridoxal-5'-Phosphate: contributes to the regulation of hormonal activity, normal psychological function, normal function of the nervous system, and a reduction of tiredness and fatigue

It is not a replacement for HRT, and the botanical ingredients above carry no authorised health claim under EU/GB law. It is a considered formula of traditionally used botanicals for women navigating perimenopause who want additional daily support alongside the lifestyle and clinical strategies in this guide.

→ Explore the MyOva Hormone Balance Supplement

For Women with PMOS (PCOS) Entering Perimenopause: MyOva Menoplus

Perimenopause presents a specific and under-recognised challenge for women who already have PMOS (polyendocrine metabolic ovarian syndrome, the condition long known as PCOS). The insulin resistance, androgen excess, and metabolic disruption of PCOS doesn't resolve at perimenopause; it intersects with the hormonal transition in ways that can significantly amplify symptoms and long-term metabolic risk.

MyOva Menoplus was created specifically for this crossover, the first menopause supplement formulated for women with PCOS. Here is what each ingredient is doing, and how confidently the evidence supports it:

• Myo-Inositol (2000mg) and D-Chiro Inositol: inositols widely studied in PCOS for their role in insulin signalling. A systematic review and meta-analysis conducted to inform the 2023 update of the international evidence-based PCOS guidelines found the evidence for myo-inositol specifically to be limited and inconclusive overall, with a more consistent signal for D-chiro-inositol's effect on ovulation, and no meaningful difference between inositol and metformin on the outcomes measured [18]. Included on that mixed but genuine evidence base, not as a guaranteed result
• Shatavari (5:1 extract): traditionally used for hormonal transition across the lifecycle, no authorised health claim
• Sage leaf (10:1, 4% rosmarinic acid): the same standardised extract used in Hormone Balance, traditionally used with an emerging evidence base for hot flush support [17]
• Red Clover (8% isoflavones): traditionally used for vasomotor symptom support, with the modest supporting evidence described above [16]
• Maca (10:1 extract): an adaptogenic root traditionally used to support energy and mood during midlife, no authorised health claim
• Hop (4:1 extract): Humulus lupulus contains 8-prenylnaringenin, a plant phytoestrogen that has attracted research interest; traditionally used alongside red clover and sage in menopause formulas
• Vitamin B6 as Pyridoxal-5'-Phosphate: contributes to the regulation of hormonal activity and normal psychological function
• Calcium L-Methylfolate: a bioavailable form of folate that contributes to normal psychological function and a reduction of tiredness and fatigue
• Vitamin B12 (Methylcobalamin): contributes to normal energy-yielding metabolism, a reduction of tiredness and fatigue, and normal psychological function

For women with PMOS (PCOS), the perimenopausal transition is not the same as for women without it. Insulin resistance can worsen as oestrogen declines, while the metabolic protective effect of oestrogen is reduced. Menoplus is formulated with this dual picture in mind, alongside the lifestyle strategies that matter most for metabolic health through this transition.

→ Explore the MyOva Menoplus Supplement

---

Lifestyle Foundations That Matter Most in Perimenopause

Resistance training. One of the most consistently recommended exercise interventions in perimenopause. Lean muscle mass supports insulin sensitivity, metabolic rate, bone density, and physical resilience. High-intensity training can amplify cortisol in women whose HPA axis is already reactive; resistance-based movement is often better suited to this phase.

Protein prioritisation. Muscle protein synthesis requires adequate protein, especially as muscle becomes harder to build with oestrogen decline. Many clinicians suggest targeting 1.6 to 2g per kg of body weight daily in active perimenopausal women; speak to a dietitian for personalised guidance.

Blood sugar stability. Managing post-meal glucose spikes can reduce insulin demand, cortisol-driven glucose fluctuation, and abdominal fat accumulation. Fibre-first eating, protein at every meal, and reducing ultra-processed food load are among the most practical levers.

Sleep protection. Sleep regulates cortisol rhythm, inflammatory markers, and hormonal balance. Protecting sleep architecture through perimenopausal disruption is a clinical priority, not a lifestyle preference.

Stress management. The HPA axis is more reactive for many women as oestrogen declines, and cortisol is cleared less efficiently [10]. Adaptogenic botanical support, parasympathetic activation (slow breathing, yoga), and workload management all have direct relevance in this context.

---

How to Have a Better Conversation with Your GP

Short answer: Track your symptoms for two to three months, use specific language, and cite NICE NG23 if you're offered a blood test instead of a clinical diagnosis.

This section is practical and direct, because many women in perimenopause have had dismissive medical encounters, and preparation makes a meaningful difference.

Track before you go. Two to three months of daily symptom tracking, noting symptom type, severity, cycle day, sleep, and mood, gives you evidence rather than a description. Bring that data.

Use the right language. "I believe I'm in perimenopause and I'd like to discuss my options" is more specific and harder to dismiss than "I haven't been feeling well."

Know your rights. NICE guidelines state that women aged 45 and over presenting with typical perimenopause symptoms should be diagnosed clinically without requiring confirmatory hormone tests [1]. If you are offered a blood test as a reason to delay diagnosis, cite NICE NG23.

Ask specific questions. "What are my options for managing vasomotor symptoms?" "Can we discuss HRT, both the benefits and my personal risk factors?" "Is there a menopause specialist or BMS-accredited clinic I can be referred to?"

Request a referral if needed. If your GP lacks confidence or knowledge in menopause medicine, which training variability across the profession suggests is common, you are entitled to ask for a referral to a specialist.

When to Seek Urgent Medical Advice

Most perimenopausal symptoms, while disruptive, are not medically urgent. However, the following require prompt medical attention:

• Bleeding between periods, after sex, or after a period of amenorrhoea
• Very heavy or prolonged bleeding that causes anaemia
• Mood symptoms severe enough to affect safety (seek immediate support via your GP, 111, or Samaritans on 116 123)
• Chest pain, palpitations, or symptoms of cardiovascular concern
• Any symptom that feels acutely wrong, regardless of what you've read

The Bottom Line

Perimenopause is not a malfunction. It is a transition, a significant, multi-year physiological recalibration that reshapes your endocrine system, brain chemistry, metabolic function, and long-term health landscape simultaneously.

It starts earlier than most women expect. It lasts longer. It affects more systems. And it is navigated most effectively not by waiting for it to pass, but by understanding what is driving each symptom, addressing the underlying mechanisms where possible, and making the specific lifestyle and nutritional choices that pay dividends well beyond the transition itself.

You deserve more than "it's your age." You deserve a clear explanation, a considered set of options, and a plan you can build confidence in. That starts with understanding what is actually happening. Your body is trying to tell you something, and it's not imagining it.

Frequently Asked Questions

How do I know if I'm in perimenopause?

The most reliable indicators are cycle changes (irregular, heavier, lighter, or skipped periods) combined with mood, sleep, or vasomotor symptoms in a woman aged 40 or over. NICE guidelines support clinical diagnosis based on symptoms in women over 45 without requiring blood tests [1].

Can I get pregnant during perimenopause?

Yes. Until menopause is confirmed (12 months without a period), pregnancy remains possible. Contraception should continue until menopause is confirmed if pregnancy is not wanted.

Does perimenopause affect women differently based on ethnicity?

Research suggests it can. Some studies indicate Black women tend to experience longer and more severe vasomotor symptoms, and that South Asian women may experience earlier onset in some populations. These differences deserve recognition in clinical assessment.

What is the difference between perimenopause and menopause?

Perimenopause is the transition phase, from first hormonal changes until 12 months after the last period. Menopause is the specific point, confirmed retrospectively, at which 12 consecutive months without a period have elapsed.

Is perimenopause the same as "the change"?

"The change" typically refers to the entire menopausal transition, which includes perimenopause, menopause itself, and postmenopause. Perimenopause is the longest and often most symptomatic phase of this transition.

Can perimenopause start in my thirties?

Early perimenopause can begin in the late thirties for some women. Symptoms before 40 warrant investigation to rule out primary ovarian insufficiency (POI), which has different management implications and requires specialist review.

What if my GP dismisses my symptoms?

Ask specifically for a referral to a menopause specialist or BMS-accredited clinic. You can also self-refer to private menopause clinics, and a growing number of NHS integrated care systems have dedicated menopause services. The Menopause Charity and Menopause Support UK both provide GP referral letter templates.

Related Blogs

• Does Sage Actually Help With Hot Flushes? Here's What the Research Says
• Red Clover for Menopause: Plant Oestrogen or Overhyped Herb?
• Mastering Hormone Balance: A Comprehensive Guide to Understanding Your Hormones
• Ashwagandha Benefits for Women: A Comprehensive Guide
• Holy Basil for Hormones: What the Research Actually Shows
• Anti-Inflammatory Eating for Hormonal Health

This article is for educational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet. Always consult your healthcare provider before starting any new supplement or making changes to existing medical treatment, particularly if you are pregnant, breastfeeding, trying to conceive, or taking prescribed medication. If you are experiencing mood symptoms that affect your safety, please contact your GP, call 111, or reach Samaritans on 116 123 (free, 24/7).

References

1. National Institute for Health and Care Excellence. Menopause: Diagnosis and Management. NICE Guideline NG23. Updated 2019. Available at: nice.org.uk/guidance/ng23
2. Chemist4U. "Menopause Statistics 2025: The Latest Facts and Stats." 2026. Available at: chemist-4-u.com
3. Harlow SD, Gracia CR, Zeleznik OA, et al. "Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging." Climacteric. 2012;15(2):105-114. https://doi.org/10.3109/13697137.2011.650656
4. Santoro N. "Perimenopause: From Research to Practice." Journal of Women's Health. 2016;25(4):332-339. https://doi.org/10.1089/jwh.2015.5556
5. Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. "Perimenopause as a Neurological Transition State." Nature Reviews Endocrinology. 2015;11(7):393-405. https://doi.org/10.1038/nrendo.2015.82
6. Schüle C, Nothdurfter C, Rupprecht R. "The Role of Allopregnanolone in Depression and Anxiety." Progress in Neurobiology. 2014;113:79-87. https://doi.org/10.1016/j.pneurobio.2013.09.003
7. Santoro N, Epperson CN, Mathews SB. "Menopausal Symptoms and Their Management." Endocrinology and Metabolism Clinics of North America. 2015;44(3):497-515. https://doi.org/10.1016/j.ecl.2015.05.001
8. Kravitz HM, Zhao X, Bromberger JT, et al. "Sleep Disturbance During the Menopausal Transition in a Multi-Ethnic Community Sample of Women." Sleep. 2008;31(7):979-990.
9. Bromberger JT, Kravitz HM. "Mood and Menopause: Findings from the Study of Women's Health Across the Nation (SWAN) over 10 Years." Obstetrics and Gynecology Clinics of North America. 2011;38(3):609-625. https://doi.org/10.1016/j.ogc.2011.05.011
10. Gordon JL, Girdler SS, Meltzer-Brody SE, et al. "Ovarian Hormone Fluctuation, Neurosteroids, and HPA Axis Dysregulation in Perimenopausal Depression: A Novel Heuristic Model." American Journal of Psychiatry. 2015;172(3):227-236. https://doi.org/10.1176/appi.ajp.2014.14070918
11. Weber MT, Maki PM, McDermott MP. "Cognition and Mood in Perimenopause: A Systematic Review and Meta-Analysis." Journal of Steroid Biochemistry and Molecular Biology. 2014;142:90-98. https://doi.org/10.1016/j.jsbmb.2013.06.001
12. Luo Y, et al. "Association of Changes in Relevant Indicators With Cardiovascular Disease and Osteoporosis in Perimenopausal and Postmenopausal Women." Food Science & Nutrition. 2024. https://doi.org/10.1002/fsn3.4512
13. British Menopause Society. "BMS Tool for Clinicians: What Is the Menopause?" 2023. Available at: thebms.org.uk
14. Greendale GA, Sowers M, Han W, et al. "Bone Mineral Density Loss in Relation to the Final Menstrual Period in a Multiethnic Cohort: Results from the Study of Women's Health Across the Nation (SWAN)." Journal of Bone and Mineral Research. 2012;27(1):111-118. https://doi.org/10.1002/jbmr.534
15. Bider-Canfield Z, et al. "Perimenopausal Bone Loss Is Associated with Ovulatory Activity: Results of the PeKnO Study." Nutrients. 2022. https://doi.org/10.3390/nu14030561
16. Kanadys W, et al. "Evaluation of Clinical Meaningfulness of Red Clover Extract to Relieve Hot Flushes in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis." Nutrients. 2021;13(4):1258. https://doi.org/10.3390/nu13041258
17. Bommer S, Klein P, Suter A. "First Time Proof of Sage's Tolerability and Efficacy in Menopausal Women with Hot Flushes." Advances in Therapy. 2011;28(6):490-500. https://doi.org/10.1007/s12325-011-0027-z
18. Fitz VW, Graca S, Mahalingaiah S, et al. "Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis to Inform the 2023 Update of the International Evidence-Based PCOS Guidelines." Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655.

References